1. Exploiting IL-17-producing CD4⁺ and CD8⁺ T cells to improve cancer immunotherapy in the clinic

   • Kinga Majchrzak
   • Michelle H. Nelson
   • Chrystal M. Paulos

   Review 29 January 2016 Pages: 247 - 259

   

2. Identification of the murine H-2D^b and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes

   • Shiwen Peng
   • Austin Mattox
   • Sara I. Pai

   Original Article 13 January 2016 Pages: 261 - 271

   

3. The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib

   • Annkristin Heine
   • Judith Schilling
   • Bastian Höchst

   Original Article 19 January 2016 Pages: 273 - 282

   

4. Cathepsin G-mediated proteolytic degradation of MHC class I molecules to facilitate immune detection of human glioblastoma cells

   • David Palesch
   • Johanna Wagner
   • Timo Burster

   Original Article 02 February 2016 Pages: 283 - 291

   

5. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors

   • Timothy T. Spear
   • Glenda G. Callender
   • Michael I. Nishimura

   Original Article 03 February 2016 Pages: 293 - 304

   

6. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155

   • Baofu Zhang
   • Weina Zhao
   • Junnian Zheng

   Original Article 03 February 2016 Pages: 305 - 314

   

7. The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity

   • Daphné Laubreton
   • Sylvie Bay
   • Claude Leclerc

   Original Article Open access 04 February 2016 Pages: 315 - 325

   

8. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

   • Kalijn F. Bol
   • Erik H. J. G. Aarntzen
   • Gerty Schreibelt

   Original Article Open access 10 February 2016 Pages: 327 - 339

   

9. Requirement of interleukin 7 signaling for anti-tumor immune response under lymphopenic conditions in a murine lung carcinoma model

   • Toshihiro Suzuki
   • Hidehiro Kishimoto
   • Ryo Abe

   Original Article 15 February 2016 Pages: 341 - 354

   

10. Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway

    • Davide Bommarito
    • Allison Martin
    • Roberto Bellucci

    Original Article 16 February 2016 Pages: 355 - 366